$NUWE

Nuwellis, Inc.

Nuwellis develops, manufactures and commercializes medical devices for ultrafiltration therapy, which removes excess fluid from patients with fluid overload who have not responded to medical treatment, including diuretics. Its Aquadex System includes the Aquadex FlexFlow and Aquadex SmartFlow systems, along with a console, disposable blood circuit and disposable catheter. The SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kg or more. Nuwellis serves healthcare professionals treating patients in pediatrics, critical care and heart failure, in inpatient and outpatient settings. Nuwellis makes money by commercializing its medical devices and related disposable components. It is also developing Vivian, a dedicated continuous renal replacement therapy device for pediatric patients weighing 2.5kg and above who need kidney replacement therapy. The company is headquartered in Eden Prairie, Minnesota.

4
0
1

No SEC Form 4 filings for $NUWE in the last 30 days.

See all $NUWE insider activity →
Low

Nuwellis Updates Investor Presentation, Citing 13% YTD Revenue Growth

Nuwellis updated its investor presentation, reporting 13% YTD revenue growth, 72% gross margin, and a cash runway through Q2 2027. The company highlighted a $4.4B U.S. market opportunity and upcoming product launches, including SmartView and Pressure IQ. Nuwellis also seeks FDA clearance for Aquadex's expanded pediatric use.

November 2026 INVESTOR PRESENTATION NASDAQ: NUWE

Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 November 2026 INVESTOR PRESENTATION NASDAQ: NUWE NASDAQ: NUWE Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange A

Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in…

Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss Console unit sales increased 88% year-to-date versus pri

NUWE sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 5 news stories mentioning NUWE (Nuwellis, Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 1 bearish.

Recent NUWE coverage spans financial news, earnings and regulation.

What's driving NUWE

  • The update improves near-term visibility (runway) and highlights margin expansion, but also flags ongoing regulatory work for ClarityPRIME and a new 510(k) pediatric indication.

    tradingview.com · Nov 17, 2026

  • Investor-presentation disclosures emphasize improving gross margins, pediatric revenue mix, and funding runway, which can support a constructive re-rating but are not a new financial print.

    SEC EDGAR 8-K · Nov 17, 2026

  • Operating loss narrowed and margins improved, indicating better cost discipline and pricing power.

    SEC EDGAR 8-K · Nov 12, 2026

  • Nuwellis reported Q3 2026 gross margin expansion to 70% and a 24% year-over-year improvement in operating loss. Pediatric sales grew 20% in the quarter, and the company submitted a 510(k) application to expand the Aquadex SmartFlow system indication. Management expects product launches in early 2027 and has $8.3 million in cash for a runway through Q2 2027. The company raised $8.1 million in the quarter.

    finance.yahoo.com · Nov 12, 2026

  • Earnings miss and flat revenue likely pressure the stock.

    seekingalpha.com · Nov 12, 2026

AlphAI scores every news story that mentions NUWE with an AI model for sentiment and relevance, and aggregates insider trades from Nuwellis, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $NUWE

Score

November 2026 INVESTOR PRESENTATION NASDAQ: NUWE

Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 November 2026 INVESTOR PRESENTATION NASDAQ: NUWE NASDAQ: NUWE Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange A

$NUWEMedEarnings

Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in…

Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss Console unit sales increased 88% year-to-date versus pri

Nuwellis, Inc. Q3 2026 Earnings Call Summary

Nuwellis reported Q3 2026 gross margin expansion to 70% and a 24% year-over-year improvement in operating loss. Pediatric sales grew 20% in the quarter, and the company submitted a 510(k) application to expand the Aquadex SmartFlow system indication. Management expects product launches in early 2027 and has $8.3 million in cash for a runway through Q2 2027. The company raised $8.1 million in the quarter.

$NUWEHighAI 8/10

Nuwellis submits FDA application for pediatric Aquadex expansion

Nuwellis (NASDAQ: NUWE) submitted a 510(k) application to the FDA to expand the use of its Aquadex SmartFlow System to pediatric patients weighing 5 kg and above, currently cleared for 20 kg and above. The submission includes clinical data from the ULTRA-Peds Registry and aims to provide treatment options for fluid overload in smaller children. The company's CEO and a medical director commented on the strategic importance and clinical benefits of the expansion.

Nuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian™ Pediatric CRRT System

Nuwellis, Inc. (NUWE) will convene a Medical & Nursing Advisory Board on November 18–19, 2026, to advance the development of its Vivian pediatric CRRT system. The board will provide feedback to validate design decisions and prioritize enhancements. Nuwellis also seeks to expand the Aquadex indication to pediatric patients weighing 5 kg or more.

$NUWEMedEarnings

Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin

Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE August 13, 2026 Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin Recent capital raise and warrant exercises extend cash runway through second quarter

Related tickers